Motif Bio PLC

Motif Bio's lender postpone's loan amortisation date by one month

Hercules Capital made this change in support of Motif Bio managing its cash runway as it advances its pipeline expansion strategy.

With a meeting planned next month with the FDA, this is an important time for Motif

Motif Bio PLC (LON:MTFB, NASDAQ:MTFB), the antibiotics developer, has amended its financing arrangement with Hercules Capital.

Hercules has agreed to amend the company's loan and security agreement by shifting back the next amortisation by one month to the first day of next month.

This change means that the August payment will be interest only.

READ Motif Bio to meet US regulator on September 19 to discuss trial design

"As we continue to evaluate options to build our pipeline, we are fortunate to have the support of our investors, who understand and appreciate the opportunities that may lay ahead,” said Graham Lumsden, the chief executive officer of Motif.

Quick facts: Motif Bio PLC

Price: £0.03

Market: AIM
Market Cap: £9.42 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...



Investor Update: AfriTin Mining produces first concentrate from Uis mine

Headlines from the Proactive UK newsroom. AfriTin Mining (LON:ATM) has produced is first tin concentrate from the Uis mine in Namibia. The miner has also signed an offtake deal with a Thai group.  BlueRock Diamonds (LON:BRD) has sold a fifth diamond this year for more than US$50,000....

4 weeks ago

2 min read